Open Innovation for Target and Lead Discovery
Steve Rees,
Vice President,
AstraZeneca
Across pharma there is an increased interest in Open Innovation strategies to access external innovation to complement internal drug discovery efforts. Within AstraZeneca we have developed a strategy to leverage the value in our compound collection to access novel compound collections and drug targets to increase the success of drug discovery. The AstraZeneca compound collection consists of 1.9M lead-like molecules that have been designed to represent known drug-like space and with the physical chemistry properties to be attractive start points for chemical optimization. To access novel compounds as potential starting points for internal drug discovery programs we have engaged in a number of collection exchanges in which AstraZeneca and a third party enable access to each others compound libraries. To access novel drug target projects we have made available all or part of the compound collection to academic partners for screening in their or our facility. A number of strategic alliances have been established, which complement a more ad-hoc access to external innovation through the AstraZeneca Open Innovation Platform to create a portfolio of greater than 20 external hit discovery projects. In this presentation I will describe the strategies, and successes, of the AstraZeneca Open Innovation Platform to complement internal discovery strategies.
|
|
